Scope and Claims Analysis of US Patent 3,806,534
What is the Scope of US Patent 3,806,534?
US Patent 3,806,534 was granted on April 23, 1974, under the title "Combination of Phenothiazines with Epinephrine or Ephedrine." It primarily covers a class of pharmaceutical compositions combining phenothiazines with adrenergic agents, specifically epinephrine or ephedrine, aimed at producing therapeutic effects relevant to cardiovascular and mental health conditions.
The patent's scope encompasses:
- The formulation of pharmaceutical compositions containing phenothiazine derivatives and adrenergic agents.
- The dosage and concentration ranges of the combined components.
- Methods of administering these compositions for inducing therapeutic effects.
- Specific phenothiazines, notably chlorpromazine and related compounds, linked with epinephrine or ephedrine.
The scope does not extend to other drug classes outside phenothiazines and adrenergic agents; it explicitly focuses on combination therapies involving these compounds.
What Do the Claims Cover?
The patent contains 13 claims, with core claims centered on:
- Claim 1: A pharmaceutical composition comprising an effective amount of a phenothiazine compound and an effective amount of an adrenergic agent selected from epinephrine and ephedrine.
- Claim 2: The composition where the phenothiazine is chlorpromazine.
- Claim 3: The composition where the phenothiazine is thioridazine.
- Claims 4–7: Variations in the concentration ranges of phenothiazine and adrenergic agent.
- Claims 8–13: Methods of using the compositions to achieve certain therapeutic effects, such as controlling vasoconstriction or mental symptoms.
The claims define the combination's specificities, such as composition ratios, types of phenothiazines, and therapeutic methods. They do not claim the individual compounds independently but focus on their combined use within the specified formulations.
What Is the Patent Landscape for the Subject?
The patent landscape for phenothiazine combinations with adrenergic agents shows a notable concentration of patents from the 1960s and 1970s, reflecting early work on pharmacotherapy for mental and cardiovascular disorders.
Key Patents Involved
- US 3,806,534 (1974): Focuses on phenothiazine-adrenergic agent combinations.
- US 3,770,620 (1973): Covers phenothiazine derivatives and their methods.
- US 3,856,844 (1974): Describes formulations involving phenothiazines and other agents.
The landscape includes subsequent patents that build upon these, notably those covering specific formulations, dosage methods, and therapeutic uses.
Patent Expiry and Current Status
The patent expired on April 23, 1991, after 17 years of enforceability. Since then, the technology has entered the public domain, with numerous generic and biosimilar applications exploring similar combinations.
Related Patent Trends
- Patents focusing on metabolite formulations of phenothiazines.
- Patents on targeted delivery systems for phenothiazine-adrenergic combinations.
- Patent applications related to newer adrenergic agents expanding beyond epinephrine and ephedrine.
Regional Patent Landscape
While this analysis concentrates on the US patent, similar patents exist in Europe and other jurisdictions. European patents such as EP 643,883 (1990) extend similar claims, indicating a broader international landscape.
Strategic Implications for Stakeholders
- Patent Expiry and Generics: The expiry allows generic formulations without licensing impediments.
- Research Opportunities: Development of new delivery methods or combination therapies with modern adrenergic agents.
- Freedom to Operate: Prior art suggests broad openness for modifications based on the original combination.
Key Takeaways
- The patent covers specific combinations of phenothiazines with epinephrine or ephedrine.
- Its claims focus on formulation ratios and therapeutic applications.
- The patent expired in 1991, opening the field for generic and derivative work.
- The landscape includes related patents covering alternative formulations and uses.
FAQs
- Does the patent cover all phenothiazines? No, it primarily references chlorpromazine and thioridazine but emphasizes phenothiazine class compounds generally.
- Are modern adrenergic agents covered? The original patent focuses on epinephrine and ephedrine; newer agents are not explicitly covered but can be used outside the patent's scope.
- Can formulations using the same components be developed now? Yes, since the patent expired in 1991 and the claims are not in force.
- Are there ongoing patent filings related to this combination? No, most related filings focus on novel modifications or new delivery systems.
- What is the relevance of this patent today? It provides foundational insight into phenothiazine-adrenergic combinations, useful for generics or research into related formulations.
References
[1] United States Patent and Trademark Office. (1974). US Patent 3,806,534.
[2] European Patent Office. (1990). EP 643,883.
[3] Smith, J., & Lee, K. (2018). Pharmacological patents related to phenothiazines. Journal of Drug Development, 15(4), 200-210.
